Stevanato Group, an Italian company that makes glass vials for COVID-19 vaccines, is expected to conduct an initial public offering in the United States. Few details have been made public, but we'll update this page as new information emerges.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $15.39 |
|---|---|
| 52-week range | $13.36 - $29.18 |
| 50-day moving average | $15.78 |
| 200-day moving average | $19.68 |
| Wall St. target price | $19.66 |
| PE ratio | 30.4752 |
| Dividend yield | $0 (0.35%) |
| Earnings per share (TTM) | $0.51 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $15.39 from 2022-07-01
| 1 week (2022-06-27) | -1.79% |
|---|---|
| 1 month (2022-06-03) | -5.58% |
| 3 months (2022-04-05) | -17.26% |
| 6 months (2022-01-05) | -18.96% |
| 1 year (2021-07-01) | N/A |
|---|---|
| 2 years (2020-07-01) | N/A |
| 3 years (2019-07-01) | N/A |
| 5 years (2017-07-01) | N/A |
Valuing Stevanato Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Stevanato Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Stevanato Group's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 30x. In other words, Stevanato Group shares trade at around 30x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Stevanato Group's P/E ratio is best considered in relation to those of others within the medical instruments & supplies industry or those of similar companies.
Stevanato Group's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.4841. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Stevanato Group's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Stevanato Group's PEG ratio in relation to those of similar companies.
Stevanato Group's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $203.7 million.
The EBITDA is a measure of a Stevanato Group's overall financial performance and is widely used to measure a its profitability.
To put Stevanato Group's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $863.1 million |
|---|---|
| Operating margin TTM | 18.38% |
| Gross profit TTM | $265.4 million |
| Return on assets TTM | 8.1% |
| Return on equity TTM | 20.51% |
| Profit margin | 14.54% |
| Book value | $3.34 |
| Market capitalisation | $4.1 billion |
TTM: trailing 12 months
Dividend payout ratio: 10.72% of net profits
Recently Stevanato Group has paid out, on average, around 10.72% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.35% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Stevanato Group shareholders could enjoy a 0.35% return on their shares, in the form of dividend payments. In Stevanato Group's case, that would currently equate to about $0 per share.
While Stevanato Group's payout ratio might seem low, this can signify that Stevanato Group is investing more in its future growth.
Stevanato Group's most recent dividend payout was on 12 July 2022. The latest dividend was paid out to all shareholders who bought their shares by 12 June 2022 (the "ex-dividend date").
Stevanato Group's dividend payout ratio is perhaps best considered in relation to those of similar companies.
Stevanato Group S. p. A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.